Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Hunan Province Tumor Hospital

Status: Enrolling

Conditions: Non-small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04322591

POSEIDON

Details and patient eligibility

About

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

Full description

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• RET Fusion Positive
• First Diagnosis and Treatment
• Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody

Exclusion criteria

• • Patients received antitumor treatment before
• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women